Harnessing the Therapeutic Potential of 'Rogue' Antibodies
Copyright © 2020 Elsevier Ltd. All rights reserved..
Therapeutic antibodies have revolutionized modern medicine. At present, antibodies are successfully used for treatment of diverse human diseases, ranging from cancer to viral infections. All clinically approved antibodies rely on highly specific recognition of their target antigen. Antigen-binding promiscuity, binding to autoantigens, and propensity for self-binding (homophilic interaction) are highly undesirable characteristics of antibody drug candidates. Nevertheless, the immune system of all healthy individuals constantly produces and uses large quantities of antibodies that can be classified as inappropriate for development as drugs. Here, I provide arguments that antibodies with 'aberrant' properties have therapeutic potential. They could be useful in certain complex pathological conditions, thus enriching our armamentarium for treatment of human diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Trends in pharmacological sciences - 41(2020), 6 vom: 25. Juni, Seite 409-417 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dimitrov, Jordan D [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies |
|---|
| Anmerkungen: |
Date Completed 05.05.2021 Date Revised 05.05.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.tips.2020.03.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309189454 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309189454 | ||
| 003 | DE-627 | ||
| 005 | 20231225133349.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.tips.2020.03.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1030.xml |
| 035 | |a (DE-627)NLM309189454 | ||
| 035 | |a (NLM)32334839 | ||
| 035 | |a (PII)S0165-6147(20)30069-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dimitrov, Jordan D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Harnessing the Therapeutic Potential of 'Rogue' Antibodies |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.05.2021 | ||
| 500 | |a Date Revised 05.05.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Therapeutic antibodies have revolutionized modern medicine. At present, antibodies are successfully used for treatment of diverse human diseases, ranging from cancer to viral infections. All clinically approved antibodies rely on highly specific recognition of their target antigen. Antigen-binding promiscuity, binding to autoantigens, and propensity for self-binding (homophilic interaction) are highly undesirable characteristics of antibody drug candidates. Nevertheless, the immune system of all healthy individuals constantly produces and uses large quantities of antibodies that can be classified as inappropriate for development as drugs. Here, I provide arguments that antibodies with 'aberrant' properties have therapeutic potential. They could be useful in certain complex pathological conditions, thus enriching our armamentarium for treatment of human diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a HIV-1 | |
| 650 | 4 | |a autoantibodies | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a homophilic antibodies | |
| 650 | 4 | |a polyreactive antibodies | |
| 650 | 4 | |a systemic inflammation | |
| 650 | 4 | |a therapeutic antibodies | |
| 650 | 7 | |a Antibodies |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Trends in pharmacological sciences |d 1989 |g 41(2020), 6 vom: 25. Juni, Seite 409-417 |w (DE-627)NLM012599670 |x 1873-3735 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2020 |g number:6 |g day:25 |g month:06 |g pages:409-417 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.tips.2020.03.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2020 |e 6 |b 25 |c 06 |h 409-417 | ||